Affimed has partnered and collaborated with global pharmaceutical and biotechnology companies to revolutionize cancer treatment across a broad range of tumor types. These partnerships and collaborations keep our clinical programs moving forward, expand our internal pipeline, and allow for the technological advancement of our platform—all with the goal of realizing the full potential of innate immune cells in oncology.

We continue to seek partnerships that are in line with our overall
corporate strategy.

For partnership inquiries, please contact email hidden; JavaScript is required.

I-O=immuno-oncology; ICE®=innate cell engager.